Navigation Links
Prescient Medical, Inc. Achieves Successful Clinical Debut of vProtect(TM) Luminal Shield
Date:5/29/2008

Novel self-expanding intracoronary prosthesis successfully placed in three

patients with coronary artery disease

DOYLESTOWN, Pa., May 29 /PRNewswire/ -- Three patients with established cardiac ischemia recently became the first recipients of the vProtect Luminal Shield, a self-expanding intracoronary prosthesis designed to limit arterial injury that typically occurs when stents are deployed. The Shield also provides robust biocompatible support for the vessel to ensure that the target coronary artery will remain patent after placement.

The patients were treated May 8-9 by Juan F. Granada, MD (Cardiovascular Research Foundation, New York, NY) and Juan A. Delgado, MD (Corbic Institute-MUA) at the Corbic Institute-MUA in Envigado, Colombia. The target lesions ranged from 60% to 80% stenosis before the vProtect Luminal Shields were deployed.

In the first patient, a 75% occlusion in the mid-circumflex coronary artery underwent pre-dilatation at low pressure with a 2.5 x 9 mm balloon and then received a 3.5 x 15 mm luminal shield. After gentle post-dilatation, angiography revealed that blood flow had been restored to the distal portion of the treated vessel.

In the second patient, an 80% occlusion in the middle of the left anterior descending (LAD) branch required pre-dilatation with a 2.5 x 9 mm balloon. Additional lumen gain was achieved by Shield placement and post-dilatation, again achieving restoration of blood flow distal to the treated segment.

The third patient was a challenging case with a 65% occlusion in the mid-LAD, located in a bend near a side branch ostium. The vProtect Luminal Shield was chosen for this patient based on its mechanical properties, including high vascular conformability. Because of its flexibility, the vProtect Luminal Shield was able to access the tortuous anatomy and cross the lesion successfully. Restoration of flow was achieved without angiographic evidence of straightening of the target vessel, a common occurrence with rigid balloon-expandable stents. In addition, the side branch was preserved without evidence of plaque shifting or worsening stenosis.

"The vProtect Luminal Shield and delivery system performed extremely well," according to Dr. Granada. "The three patients we treated presented with lesions representative of what we see in daily clinical practice and we were able to cross these lesions and deliver the device safely in each case. Although the vProtect Luminal Shield has ultra-thin struts to promote healing, it maintains an intrinsic radial force that matches the vessel compliance. I am very pleased with these early results," Dr. Granada said.

For more information about Prescient Medical and its products, contact Ilana Odess at (917) 941-9990.

About Prescient Medical, Inc.

Prescient Medical, Inc. is a privately held medical device company dedicated to reducing deaths from heart attacks, the leading cause of death in much of the world. For more information, please visit our website at http://www.prescientmedical.com or call +1-866-376-0500.


'/>"/>
SOURCE Prescient Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Prescient Medical, Inc. Acquires New Technology to Detect Inflammation in Coronary Blood Vessels
2. Pharmacopeias First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients
3. CureDMs Diabetes Therapy Achieves Major Development Milestone
4. EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program
5. Bionomics Achieves US$1 Million Milestone Payment from Genmab
6. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
7. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
8. Surface Logix Achieves Objectives With SLx-2101 in Phase 2a Clinical Trial in Hypertension
9. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
10. PLC Systems Achieves Successful Early Conclusion of RenalGuard(TM) Pilot Safety Trial
11. Cethromycin Achieves All Endpoints in Second Pivotal Phase III Trial for Treatment of Pneumonia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... , Schweiz, April 27, 2016 /PRNewswire/ ... des Sachs CEO Forums in Zürich gab ... ihres führenden Wirkstoffkandidaten STR001 zur Erhaltung des ... eingesetzt wurde, bekannt. Für die umfassende Phase-II-Doppelblindstudie ... und Frankreich angeworben. STR001 wird während der ...
(Date:4/27/2016)...   , Total Sales Grow ... Clinical sales grow 16% year-over-year  , ... MKEAY) inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy ... ended March 31, 2016 and provided an update on ... First Quarter 2016 Revenue Results by Category  ...
(Date:4/27/2016)... April 27, 2016 Transparency Market ... Devices Market - Global Industry Analysis, Size, Share, Growth, ... report, the global skincare devices market was valued at ... expand at a CAGR of 10.1% from 2015 to ... Browse the full Skincare Devices Market (Treatment Device - ...
Breaking Medicine Technology:
(Date:5/1/2016)... ... 01, 2016 , ... ProBrand Reveal Volume 2 is a set of versatile and smooth logo ... keyframeless animations, users can easily create a unique logo reveal in just a matter of ... presets. Use these title presets to add a uniquely animated logo to any photos or ...
(Date:4/30/2016)... ... April 30, 2016 , ... ... Radio with Hypnotherapist, Mary O'Maley. What is hypnosis and hypnotherapy and why ... smoking, weight control), pain relief (chronic and acute), birthing processes and medical procedures, ...
(Date:4/30/2016)... ... , ... well is a challenge for all of us, but there are things we can do to ... “Research is showing more and more that there are simple, yet important steps that can ... age.” Top priorities Dr. Kohli’s recommends for her patients include;, , exercise ...
(Date:4/29/2016)... ... April 29, 2016 , ... Since launching its annual volunteer ... serving the footwear industry, has broken all previous participation records in its first ... 23 states during the months of April and May, the 2016 Footwear Cares ...
(Date:4/29/2016)... ... 29, 2016 , ... The American workforce is on everyone’s ... Most importantly, employees are the single most important asset in creating value and ... , Just under half of American workers are emotionally checked out with low ...
Breaking Medicine News(10 mins):